{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:46:48Z","timestamp":1791607608024,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejca.2022.03.017","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T17:28:11Z","timestamp":1649784491000},"page":"112-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"special_numbering":"C","title":["Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer \u2013 The PICCASSO phase I trial"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-9968","authenticated-orcid":false,"given":"Georg Martin","family":"Haag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3843-101X","authenticated-orcid":false,"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-8206","authenticated-orcid":false,"given":"Leonidas","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0906-4401","authenticated-orcid":false,"given":"Anne-Katrin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-123X","authenticated-orcid":false,"given":"Tim Frederik","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka","family":"Zoernig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Waberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Wilhelm","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah-Eddin","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Halama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2022.03.017_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.017_bib2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/cncr.24081","article-title":"Survival after hepatic resection of colorectal cancer metastases: a national experience","volume":"115","author":"Robertson","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.03.017_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","article-title":"Treatment sequencing in metastatic colorectal cancer","volume":"109","author":"Modest","year":"2019","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.ejca.2022.03.017_bib4","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9863","key":"10.1016\/j.ejca.2022.03.017_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.017_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.03.017_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5795","key":"10.1016\/j.ejca.2022.03.017_bib8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.017_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1286436","article-title":"Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival","volume":"6","author":"Berthel","year":"2017","journal-title":"OncoImmunology"},{"issue":"26","key":"10.1016\/j.ejca.2022.03.017_bib10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2022.03.017_bib11","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl. 8","key":"10.1016\/j.ejca.2022.03.017_bib12","volume":"29","author":"Grothey At","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.017_bib13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.03.017_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002505","article-title":"Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects","volume":"9","author":"Suarez-Carmona","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2022.03.017_bib15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41416-019-0441-6","article-title":"Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer","volume":"120","author":"Kather","year":"2019","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2022.03.017_bib16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nri1733","article-title":"Monocyte and macrophage heterogeneity","volume":"5","author":"Gordon","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.017_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trecan.2015.11.004","article-title":"Ontogeny of tumor-associated macrophages and its implication in cancer regulation","volume":"2","author":"Franklin","year":"2016","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.017_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.017_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000426","article-title":"Macrophage repolarisation therapy in colorectal cancer","volume":"3","author":"Halama","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.03.017_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36967","article-title":"Topography of cancer-associated immune cells in human solid tumors","volume":"7","author":"Kather","year":"2018","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.017_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.imbio.2015.08.011","article-title":"The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential","volume":"222","author":"Braster","year":"2017","journal-title":"Immunobiology"},{"issue":"13","key":"10.1016\/j.ejca.2022.03.017_bib22","doi-asserted-by":"crossref","first-page":"110171","DOI":"10.1016\/j.celrep.2021.110171","article-title":"Macrophages are metabolically heterogeneous within the tumor microenvironment","volume":"37","author":"Geeraerts","year":"2021","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.017_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral immune cell exploitation in colorectal cancer metastases can Be targeted effectively by anti-CCR5 therapy in cancer patients","volume":"29","author":"Halama","year":"2016","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.ejca.2022.03.017_bib24","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent advances targeting CCR5 for cancer and its role in immuno-oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2022.03.017_bib25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-017-1988-9","article-title":"CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma","volume":"66","author":"Umansky","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.017_bib26","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1593\/tlo.13499","article-title":"CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination","volume":"6","author":"Mencarelli","year":"2013","journal-title":"Transl Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2022.03.017_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2125.2008.03130.x","article-title":"Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers","volume":"65","author":"Abel","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.ejca.2022.03.017_bib28","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"30","key":"10.1016\/j.ejca.2022.03.017_bib29","doi-asserted-by":"crossref","first-page":"48335","DOI":"10.18632\/oncotarget.10227","article-title":"Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancerassociated fibroblast accumulation","volume":"7","author":"Tanabe","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.017_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12032-015-0607-x","article-title":"CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells","volume":"32","author":"Pervaiz","year":"2015","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.017_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.03.017_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e22121","article-title":"Adaptation and modification of the immune related response criteria (IRRC): IrRECIST","volume":"32","author":"Bohnsack","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.017_bib33","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24116","article-title":"Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration","volume":"2","author":"Halama","year":"2013","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.017_bib34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4161\/onci.20179","article-title":"Sequential metastases of colorectal cancer: immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments","volume":"1","author":"Keim","year":"2012","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.017_bib35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-10-2173","article-title":"Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines","volume":"17","author":"Halama","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ejca.2022.03.017_bib36","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1158\/0008-5472.CAN-11-0268","article-title":"Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy","volume":"71","author":"Halama","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2022.03.017_bib37","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.21873\/anticanres.14717","article-title":"Differential analyses of peripheral blood parameters in CCR5 inhibition-treated colorectal cancer patients reveal dynamic changes linked to clinical outcomes","volume":"40","author":"Ahmed","year":"2020","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.017_bib38","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-10-2173","article-title":"Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines","volume":"17","author":"Halama","year":"2011","journal-title":"Clin Cancer Res : An Off J Am Assoc Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.017_bib39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-20-2404","article-title":"ARID1A mutation may define an immunologically active subgroup in patients with microsatellite stable colorectal cancer","volume":"27","author":"Mehrvarz Sarshekeh","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.017_bib40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO.26 study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2022.03.017_bib41","article-title":"Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer","volume":"4","author":"Sasaki","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.017_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000350","article-title":"Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)","volume":"8","author":"Kato","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2022.03.017_bib43","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.21873\/anticanres.14657","article-title":"Tertiary lymphoid structures in colorectal cancer liver metastases: association with immunological and clinical parameters and chemotherapy response","volume":"40","author":"Ahmed","year":"2020","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.017_bib44","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability","volume":"44","author":"Mlecnik","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.017_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/intimm\/dxu090","article-title":"IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration","volume":"27","author":"Makita","year":"2015","journal-title":"Int Immunol"},{"issue":"14","key":"10.1016\/j.ejca.2022.03.017_bib46","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1073\/pnas.0913683107","article-title":"In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction","volume":"107","author":"Blatner","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.017_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2022.03.017_bib48","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.017_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9959946","article-title":"Efficacy and safety of regorafenib combined with toripalimab in the third-line and beyond treatment of advanced colorectal cancer","volume":"2021","author":"Yu","year":"2021","journal-title":"J Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2022.03.017_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2022.40.4_suppl.015","article-title":"Phase I\/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC)","volume":"40","author":"Barzi","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:48Z","timestamp":1760733408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":50,"alternative-id":["S0959804922001617"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer \u2013 The PICCASSO phase I trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}